BMY - Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination
At the start of the year, 2019, Bristol-Myers Squibb (BMY) announced it was planning to acquire Celgene (CELG). The announcement was unexpected, leading to a massive run-up in Celgene’s stock price. The details have yet to be ironed out. However, current estimates show that it will likely be the third largest healthcare acquisition ever. I originally analyzed the deal here, which I recommend reading. This article will help provide investors with an update and how the companies are on the path to a valuable combination.
Company Combination - Announcement Investor Presentation